Cargando…
Based on Principles and Insights of COVID-19 Epidemiology, Genome Sequencing, and Pathogenesis: Retrospective Analysis of Sinigrin and Prolixin(RX) (Fluphenazine) Provides Off-Label Drug Candidates
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative pathogen of pandemic coronavirus disease 2019 (COVID-19). So far, no approved therapy has been developed to halt the spread of the pathogen, and unfortunately, the strategies for developing a new therapy will require a lon...
Autores principales: | Nazeam, Jilan, Mohammed, Esraa Z., Raafat, Mariam, Houssein, Mariam, Elkafoury, Asmaa, Hamdy, Dina, Jamil, Lina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Laboratory Automation and Screening. Published by Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960168/ https://www.ncbi.nlm.nih.gov/pubmed/32804597 http://dx.doi.org/10.1177/2472555220950236 |
Ejemplares similares
-
Sinigrin and Its Therapeutic Benefits
por: Mazumder, Anisha, et al.
Publicado: (2016) -
FLUPHENAZINE DECANOATE IN CHRONIC SCHIZOPHRENIA
por: Shukla, G. D.
Publicado: (1981) -
Fluphenazine-Induced Severe Hypertriglyceridemia
por: Taneja, Charit, et al.
Publicado: (2021) -
Fluphenazine dihydrochloride dimethanol solvate
por: Petrus, Joanna, et al.
Publicado: (2012) -
The Effect of Fluphenazine and Thioridazine on Toxoplasma gondii In Vivo
por: SARAEI, Mehrzad, et al.
Publicado: (2016)